PharmaCyte Biotech Directors, Executives Make Substantial Stock Purchases
ByAinvest
Wednesday, Jan 7, 2026 5:50 pm ET1min read
PMCB--
PharmaCyte Biotech, Inc. (PMCB) announced that Director Jonathan Schechter purchased 20,000 shares at $0.79 per share on January 6, 2026, and 20,000 shares at $0.84 per share on January 7, 2026. Schechter also purchased 20,000 shares at $0.78 per share on January 5, 2026. Additionally, Director, CEO, and President Joshua Silverman acquired 30,000 shares at $0.78 per share on January 5, 2026, and 40,000 shares at $0.83 per share on January 7, 2026, as well as 30,000 shares at $0.79 per share on January 6, 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet